Midgard Science
B

Baopharma 宝济药业

Shanghai, China baopharma.com

From their website, Nov 2026

Work here? Claim this listing

About

Baopharma 宝济药业 develops recombinant protein and antibody-based therapeutics. It works on industrialization and commercialization of these products for patients, with operations in Shanghai and Suzhou, China.

Services

  • Recombinant human hyaluronidase solutions

    Develops recombinant human hyaluronidase for subcutaneous drug delivery and combination use with small molecules and biologics.

  • Recombinant IgG cleaving enzyme development

    Develops an IgG-degrading enzyme platform for rapidly cleaving circulating and tissue IgG in conditions such as autoimmune disease, transplantation, and gene therapy.

  • Recombinant chymotrypsin products

    Develops recombinant chymotrypsin using genetic engineering to replace traditional animal organ extraction methods.

  • Biopharmaceutical manufacturing

    Builds cGMP-compliant manufacturing for drug substance and finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes.

  • Drug substance production

    Operates production lines using mammalian cell expression systems and bacterial/yeast expression systems.

  • Recombinant chymotrypsin development

    Uses genetic engineering to develop chymotrypsin products as an alternative to traditional animal organ extraction methods.

  • Bispecific antibody formulation development

    Develops KJ015, an anti-HER2 bispecific antibody formulated with Hysorptase for subcutaneous administration.

  • Biologics manufacturing

    Manufactures therapeutic biological products using mammalian cell expression systems and bacterial/yeast expression systems.

  • Finished dosage form production

    Produces injectable solutions, lyophilized powder injections, and pre-filled syringes.

  • Clinical development support

    Advances products through clinical trial approvals and clinical trial programs in China and other regions.

Turnaround
Within 1 to 2 hours
What to send
Contact mailbox · Contact number · Message content

Capabilities

Assays and studies
Antibodies · Bispecifics · Small molecules · Mammalian expression · Lyophilization · Clinical trials · Phase I clinical trials
Scale and capacity
Approximately 63,000 square meters · 94 mu · 25,000-square-meter facility · Approximately 63,000 square meters facility · 94 mu (approx. 15.5 acres) of land
Therapeutic areas
Autoimmune diseases · Rare diseases · Organ transplantation · Gene therapy · Solid tumors · IgG-type multiple myeloma · Kidney transplantation · Anti-GBM disease · Kidney transplant · HER2-positive cancers · Multiple myeloma

Modalities and species

Modalities
Small molecule · Antibody · Bispecific · Recombinant protein
Species and models
Mammalian cell expression systems · Bacterial expression systems · Yeast expression systems · Streptococcus pyogenes

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: manufacturing facility

Industries served

  • Biotech
  • Pharmaceuticals

Company

Type
CDMO
Founded
2011

Locations

Address
50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021, enab
Sites
Shanghai, China · Suzhou, China
Serves
China, New Zealand, Europe

Contacts

Similar labs

Work here? Claim this listing